Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HMBD-002
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Hummingbird Bioscience
Deal Size : $290.0 million
Deal Type : Licensing Agreement
Hummingbird Licenses HMBD-002, an Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Details : Percheron gains an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002, a monoclonal antibody therapy targeting VISTA, in all territories and indications.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 25, 2025
Lead Product(s) : HMBD-002
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Hummingbird Bioscience
Deal Size : $290.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ATL1102
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy
Details : ATL1102 is a Oligonucleotide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Muscular Dystrophy, Duchenne.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 10, 2023
Lead Product(s) : ATL1102
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
